Holen Sie sich die Stockscreener-App
1.63
1.81%
-0.03
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
Will MAIA Biotechnology Inc. stock sustain dividend payoutsJuly 2025 Opening Moves & Risk Managed Investment Strategies - ulpravda.ru
Will MAIA Biotechnology Inc. stock deliver compounding returns2025 Fundamental Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
Can MAIA Biotechnology Inc. stock deliver strong annual returnsWeekly Trade Recap & Expert Curated Trade Ideas - ulpravda.ru
MAIA Biotechnology (MAIA) director granted 24,060 options under 2021 plan - Stock Titan
MAIA Biotechnology (MAIA) director reports grant of 29,216 stock options - Stock Titan
MAIA Biotechnology (MAIA) director receives 25,206 stock options exercisable at $1.53 - Stock Titan
MAIA Biotechnology, Inc. (MAIA) reports 29,789 director stock options at $1.53 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) reports 24,633 stock options grant - Stock Titan
A stock that deserves closer examination: MAIA Biotechnology Inc (MAIA) - uspostnews.com
MAIA Biotechnology, Inc. Common Stock (NYSE:MAIA) Stock Quote - FinancialContent
MAIA Biotechnology announces open market purchases by CEO, directors - MSN
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December - MarketBeat
MAIA Biotechnology (MAIA) Price Target Decreased by 13.32% to 12.38 - MSN
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - The Manila Times
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 By Investing.com - Investing.com Canada
Chaouki Steven M buys MAIA Biotechnology shares worth $49999 By Investing.com - Investing.com Australia
Stan Smith buys MAIA Biotechnology shares worth $69,999 - Investing.com
Louie Ngar Yee buys MAIA Biotechnology (MAIA) shares worth $99999 - Investing.com
MAIA Biotechnology Directors Increase Holdings - TradingView — Track All Markets
MAIA (MAIA) director boosts stake with 57,189-share buy and new options - Stock Titan
MAIA Biotechnology (MAIA) director reports stock purchase and new options - Stock Titan
MAIA Biotechnology (MAIA) director reports stock and option purchases - Stock Titan
MAIA Biotechnology, Inc. announced that it has received $1.289791 million in funding - marketscreener.com
Swing Trade: Why hedge funds are buying MAIA Biotechnology Inc stockJuly 2025 Movers & Safe Entry Momentum Stock Tips - moha.gov.vn
MAIA Biotechnology Earnings Notes - Trefis
Can MAIA Biotechnology Inc. stock double in next 5 yearsPortfolio Gains Report & Capital Efficiency Focused Ideas - DonanımHaber
How MAIA Biotechnology Inc. stock compares to industry benchmarksWeekly Profit Summary & AI Forecasted Entry/Exit Points - Улправда
Can MAIA Biotechnology Inc. stock maintain operating marginsJuly 2025 Intraday Action & Expert Approved Momentum Ideas - bolumsonucanavari.com
Why MAIA Biotechnology Inc. stock is upgraded to buy2025 Valuation Update & Daily Growth Stock Tips - DonanımHaber
Can MAIA Biotechnology Inc. stock deliver consistent earnings growth2025 Historical Comparison & Fast Exit/Entry Strategy Plans - Улправда
MAIA Biotechnology, Inc. (MAIA) Gets a Buy from Noble Financial - The Globe and Mail
MAIA Biotechnology announces $2.25M private placement deal - MSN
MAIA Biotechnology Announces $2.25M Private Placement Deal - TipRanks
MAIA Biotechnology (NYSE American: MAIA) details $2.25M private placement - Stock Titan
MAIA Biotechnology Announces $1.51 Million Private Placement - The Manila Times
MAIA Biotechnology, Inc. announced that it expects to receive $1.289791 million in funding - marketscreener.com
MAIA Biotechnology Announces Significant Insider Buying - TipRanks
MAIA Biotechnology, Inc. Announces Key Developments in Cancer Therapy - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) starts Ateganosine Phase 3 trial and notes insider buying - Stock Titan
MAIA Biotechnology (NYSE American: MAIA) begins Phase 3 NSCLC study of telomere-targeting ateganosine - Stock Titan
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer - Yahoo Finance
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential - Yahoo Finance
MAIA Biotechnology Advances NSCLC Treatment with Ateganosine - TipRanks
MAIA Biotechnology, Inc. Targets $50B Immunotherapy Market with New Approach - TradingView — Track All Markets
MAIA Biotechnology (NYSE: MAIA) highlights $50B immunotherapy market in press release - Stock Titan
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach - The Manila Times
Prepare Yourself for Liftoff: MAIA Biotechnology Inc (MAIA) - setenews.com
Director Makes Bold Move with Major Stock Purchase in MAIA Biotechnology! - TipRanks
Dir Smith Buys 13,740 ($16.4K) Of Maia Biotechnology Inc [MAIA] - TradingView — Track All Markets
0.90%
Kapitalisierung:
|
Volumen (24h):